证券代码：000615 证券简称：*ST美谷 公告编号：2025-102 2、会议召集人：公司管理人。 3、会议召开的合法、合规性：本次会议的召集程序符合《中华人民共和国 企业破产法》《中华人民共和国公司法》《深圳证券交易所股票上市规则》（以 1 关于召开出资人组会议暨 2025 年第四次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 奥园美谷科技股份有限公司 奥园美谷科技股份有限公司（以下简称"公司"）于 2025 年 11 月 14 日收 到湖北省襄阳市中级人民法院（以下简称"襄阳中院"）送达的（2024）鄂 06 破申 48 号《民事裁定书》，襄阳中院裁定受理债权人广州律建财税咨询有限公 司（以下简称"申请人"）对公司的重整申请。同日，公司收到襄阳中院送达的 （2025）鄂 06 破 17 号《决定书》，襄阳中院指定奥园美谷科技股份有限公司清 算组担任奥园美谷科技股份有限公司管理人（以下简称"管理人"）。具体内容 详见公司于 2025 年 11 月 15 日在巨潮资讯网（www.cninfo.com.cn，下同）披露 的《关于法院裁定受 ...

New Stock Listings - Nant Technology (920124) listed at an issue price of 8.66 on November 27, 2025[1] - Tianpu Co., Ltd. (605255) is in the offer period from November 20 to December 19, 2025[1] - Jianglong Shipbuilding (300589) and Huasheng Lithium Battery (688353) reported significant abnormal fluctuations[1] Abnormal Fluctuations - Multiple companies including ST Wanfang (000638) and ST Dongyi (002713) have reported abnormal trading activities[2] - Companies such as ST Suwu (600200) and ST Yanshan (000608) are also under scrutiny for unusual market behavior[3]

奥园美谷科技股份有限公司 章 程 二〇二五年十一月 | 第一节 | 股份发行 | | 2 | | --- | --- | --- | --- | | 第二节 | 股份增减和回购 | | 3 | | 第三节 | 股份转让 | | 4 | | 第一节 | 股东的一般规定 | | 5 | | 第二节 | 控股股东和实际控制人 | | 7 | | 第三节 | 股东会的一般规定 | | 8 | | 第四节 | 股东会的召集 | | 10 | | 第五节 | 股东会的提案与通知 | | 11 | | 第六节 | 股东会的召开 | | 12 | | 第七节 | 股东会的表决和决议 | | 14 | | 第一节 | 董事的一般规定 | | 18 | | 第二节 | 董事会 | | 20 | | 第三节 | 独立董事 | | 26 | | 第四节 | 董事会专门委员会 | | 28 | | 第一节 | 财务会计制度 | | 30 | | 第二节 | 内部审计 | | 33 | | 第三节 | 会计师事务所的聘任 | | 33 | | 第一节 | 通知 | | 34 | | 第二节 | 公告 | | 34 | | 第一节 | 合 ...

关于奥园美谷科技股份有限公司 2025年第三次临时股东会的法律意见书 君達律師事務所 aw Firm 广东广信君达律师事务所 关于奥园美谷科技股份有限公司 2025年第三次临时股东会的 法律意见书 (2025) 广信君达律见字第 117786-4 号 致:奥园美谷科技股份有限公司 广东广信君达律师事务所(以下简称"本所")接受奥园美谷科技股份有 限公司（以下简称"公司"）的委托，指派杨尹、吴震宇律师（以下简称"本 所律师"）出席公司 2025年第三次临时股东会（以下简称"本次股东会"）， 并获授权依据 《中华人民共和国公司法》(以下简称《公司法》)、《中华人 民共和国证券法》、《上市公司股东会规则》（以下简称《股东会规则》）、 《深圳证券交易所上市公司股东会网络投票实施细则（2025年修订）》（以下 简称《网络投票实施细则》）和《奥园美谷科技股份有限公司章程》（以下简 称《公司章程》）的有关规定出具本法律意见书。 为出具本法律意见,本所律师参加了本次股东会,并审慎查阅了公司提供 的以及本所律师认为必要的与本次股东会有关的文件资料。本所律师已获公司 作出如下承诺与保证:公司向本所律师提供的文件、资料或信息(含文 ...

证券代码：000615 证券简称：*ST美谷 公告编号：2025-100 奥园美谷科技股份有限公司 重要提示： 1、本次股东会无否决提案的情形； 2、本次股东会不涉及变更以往股东会已通过决议的情形。 一、会议的召开情况 1、会议召开时间： （1）现场会议时间：2025 年 11 月 25 日（星期二）下午 15:30 开始； （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025年11月25日的交易时间，即上午9:15-9:25，9:30-11:30，下午13:00-15:00； 通过深圳证券交易所互联网投票系统进行网络投票的时间为 2025 年 11 月 25 日 上午 9:15 至下午 15:00 间的任意时间。 2、现场会议召开地点：广东省广州市天河区黄埔大道西 108 号 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 6、股权登记日：2025 年 11 月 19 日 7、本次股东会会议召开符合有关法律、行政法规及部门规章、规范性文件 和《公司章程》的有关规定。 二、会议的出席情况 参加本次股 ...

从资金流向上来看，当日医疗美容板块主力资金净流出5875.57万元，游资资金净流入1690.61万元，散户 资金净流入4184.96万元。医疗美容板块个股资金流向见下表： 证券之星消息，11月24日医疗美容板块较上一交易日上涨0.27%，*ST美谷领涨。当日上证指数报收于 3836.77，上涨0.05%。深证成指报收于12585.08，上涨0.37%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 4.07 | 4.63% | 28.52万 | | 1.15亿 | | 688363 | 华熙生物 | 49.78 | 1.86% | 1.87万 | | 9268.75万 | | 300896 | 爱美客 | 66'56 | -1.36% | 2.41万 | | 3.52亿 | | 920982 | 锦波生物 | 216.59 | -1.55% | 7336.92 | | 1.60亿 | | 代码 | 名称 | 主力净流 ...

Core Viewpoint - Two major pharmaceutical groups, Jiuzhoutong and Guangzhou Pharmaceutical Group, are acquiring distressed companies to strengthen their respective business segments in the medical aesthetics and IVD (in vitro diagnostics) industries [1][2]. Group 1: Jiuzhoutong's Acquisition of Aoyuan Meigu - Jiuzhoutong's wholly-owned subsidiary is investing in Aoyuan Meigu, which has entered a restructuring process due to ongoing financial losses and debt crises [1][2]. - Aoyuan Meigu, which ventured into the medical aesthetics sector in 2020, has been struggling with significant operational losses and was unable to repay debts, leading to a restructuring application [2][3]. - If the restructuring is successful, Jiuzhoutong plans to leverage its strong pharmaceutical supply chain and operational management experience to enhance collaboration with Aoyuan Meigu in the beauty and health sector [4]. Group 2: Guangzhou Pharmaceutical Group's Acquisition of Da'an Gene - Guangzhou Pharmaceutical Group is acquiring 100% equity of Guangyong Technology, which will indirectly give it control over 2.33 billion shares of Da'an Gene, amounting to a total investment of 908 million yuan [1]. - Da'an Gene, initially a university-run enterprise, has faced significant declines in performance, with a 90.20% drop in revenue and a 98.07% drop in net profit in 2023 [3]. - The acquisition aims to resolve internal issues at Da'an Gene and expand Guangzhou Pharmaceutical Group's business footprint in the IVD sector, creating a comprehensive "diagnosis + treatment + health management" industry chain [5]. Group 3: Industry Environment - Both the medical aesthetics and IVD sectors have moved past the most stringent regulatory challenges, allowing for greater pricing flexibility for compliant institutions [6]. - The ongoing price reductions in the IVD sector have led to a concentration of market share among leading companies, presenting a favorable opportunity for cash-rich players to acquire distressed assets [6].

Market Overview - The medical beauty sector experienced a decline of 2.01% on November 21, with *ST Meigu leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Key stocks in the medical beauty sector showed the following performance: - Huaxi Biological (688363) closed at 48.87, down 1.81% with a trading volume of 25,700 shares and a turnover of 126 million yuan [1] - Aimeike (300896) closed at 148.00, down 1.88% with a trading volume of 29,100 shares [1] - Jinbo Biological (920982) closed at 220.01, down 4.88% with a trading volume of 11,000 shares [1] - *ST Meigu (000615) closed at 3.89, down 4.89% with a trading volume of 217,100 shares and a turnover of 85.48 million yuan [1] Capital Flow - The medical beauty sector saw a net outflow of 87.65 million yuan from main funds, while retail investors contributed a net inflow of 83.50 million yuan [1] - Detailed capital flow for key stocks includes: - *ST Meigu: Main funds net outflow of 12.38 million yuan, retail net inflow of 9.03 million yuan [2] - Huaxi Biological: Main funds net outflow of 24.09 million yuan, retail net inflow of 26.09 million yuan [2] - Jinbo Biological: Main funds net outflow of 32.71 million yuan, retail net inflow of 340,200 yuan [2] - Aimeike: Main funds net outflow of 51.18 million yuan, retail net inflow of 48.38 million yuan [2]

Group 1 - The core viewpoint of the article is that a major pharmaceutical distribution company, Jiuzhoutong, is attempting to invest in the troubled medical aesthetics company, ST Meigu, through a restructuring plan, which is viewed skeptically by the market [1][5]. - Jiuzhoutong's full subsidiary is officially participating in the restructuring investment of ST Meigu, indicating a strategic move into the medical aesthetics sector [1][5]. - Following the announcement, both Jiuzhoutong and ST Meigu's stock prices declined, reflecting market concerns about the viability of this investment [1][3]. Group 2 - ST Meigu, the target of the restructuring, has significant operational and governance issues, including a history of losses and regulatory penalties for information disclosure violations [2]. - The company has undergone multiple strategic shifts, leading to a lack of core competitive advantage and a heavy debt burden, with substantial overdue debts and frozen bank accounts [2]. - Jiuzhoutong faces challenges in integrating ST Meigu due to the differing business models and management practices between traditional pharmaceutical distribution and medical aesthetics services [3][4]. Group 3 - The medical aesthetics industry is characterized by intense competition and market volatility, with numerous players involved, raising questions about Jiuzhoutong's ability to achieve the desired synergies through this acquisition [4]. - Jiuzhoutong is optimistic about the potential of the Chinese medical aesthetics market and aims to establish a comprehensive supply chain and terminal layout through this restructuring [5]. - The success of this investment remains uncertain, as the restructuring process may face significant challenges, and failure could lead to severe consequences for Jiuzhoutong [4][5].

Group 1: Company Announcements - Aoyuan Meigu has received court approval to continue operations and manage its affairs during the restructuring period, with a risk of bankruptcy and stock delisting if the restructuring fails [3] - Inspur Software reported a net profit of -211.06 million yuan for the first three quarters of 2025, a 123% decline year-on-year, indicating a risk of performance decline [4] - Dayu Water-saving's acquisition of 70% equity in Huai'an Design Institute for 311 million yuan has passed antitrust review, allowing the transaction to proceed [5] - Hainan Development disclosed a cumulative litigation amount of 122 million yuan over the past 12 months, accounting for 11.37% of its latest audited net assets [6] Group 2: Share Buybacks - Haida Group conducted its first share buyback, repurchasing 137,600 shares for a total of approximately 7.99 million yuan [8] - Guangyu Group completed a share buyback of 10,108,000 shares, totaling 29.99 million yuan, representing 1.31% of its total share capital [9] - Puluo Pharmaceutical plans to repurchase shares worth 180 million to 360 million yuan for employee incentive plans, with a maximum price of 23 yuan per share [10] - Huarong Co. executed its first share buyback, acquiring 100,000 shares for a total of 1.89 million yuan [11] Group 3: Shareholding Changes - Kanglongda's major shareholder plans to reduce its stake by up to 3% within 90 days starting December 11, 2025 [12] - Liyuan Technology's shareholder intends to reduce its stake by up to 2.0303% between December 12, 2025, and March 11, 2026 [13] - Yinlong Co.'s controlling shareholder reduced its stake, bringing the total holding down to 25% [14] - Bicheng Co. announced multiple shareholders' plans to reduce their stakes, with specific amounts disclosed [15] Group 4: Major Contracts - Han Jian Heshan won a bid for a water supply project with a contract value of 388 million yuan, expected to significantly impact its revenue [17] - Dafeng Industrial secured a project worth 165 million yuan, representing 8.97% of its 2024 revenue, which could have a long-term positive effect on its performance [18] - Jiangnan Water signed a contract worth 368 million yuan for a drainage project, which is anticipated to positively influence its business performance [19]